Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure
Bio-Rad (BIO) is experiencing weaker sales in Asia as China is currently entangled in a challenging research funding environment, and Japan, too, is facing constrained funding issues.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered
Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.
Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman of the Board, President and CEO Andy Last - Executive Vice President and Chief Operating Officer Roop Lakkaraju - Executive Vice President and CFO Conference Call Participants Patrick Donnelly - Citi Daniel Leonard - UBS Tycho Peterson - Jefferies Jack Meehan - Nephron Research Operator Good day, everyone, and welcome to today's Bio-Rad Second Quarter 2024 Earnings Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings Estimates
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $3.11 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $3 per share a year ago.
Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products
Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients.
What's in Store for These 4 MedTech Stocks in Q2 Earnings?
Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.
All You Need to Know About Bio-Rad (BIO) Rating Upgrade to Buy
Bio-Rad (BIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.
Why Is Bio-Rad (BIO) Up 7.8% Since Last Earnings Report?
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?
Aptevo Participating in the BIO International Convention
SEATTLE, WA / ACCESSWIRE / June 3, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company is participating in the BIO International Convention occurring June 3-6, 2024 in San Diego, CA. The conference is known for being the largest biotechnology industry conference of the year and is expected to attract more than 18,000 attendees from around the world.
